Literature DB >> 15824107

Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.

Sajani S Lakka1, Christopher S Gondi, Dzung H Dinh, William C Olivero, Meena Gujrati, Velidi H Rao, Chrissa Sioka, Jasti S Rao.   

Abstract

We have previously demonstrated the effectiveness of adenovirus-mediated expression of antisense urokinase-type plasminogen activator receptor (uPAR) and matrix metalloproteinase-9 (MMP-9) in inhibiting tumor invasion in vitro and ex vivo. However, the therapeutic effect of the adenovirus-mediated antisense approach was shown to be transient and required potentially toxic, high viral doses. In contrast, RNA interference (RNAi)-mediated gene targeting may be superior to the traditional antisense approach, because the target mRNA is completely degraded and the molar ratio of siRNA required to degrade the target mRNA is very low. Here, we have examined the siRNA-mediated target RNA degradation of uPAR and MMP-9 in human glioma cell lines. Using RNAi directed toward uPAR and MMP-9, we achieved specific inhibition of uPAR and MMP-9. This bicistronic construct (pUM) inhibited the formation of capillary-like structures in both in vitro and in vivo models of angiogenesis. We demonstrated that blocking the expression of these genes results in significant inhibition of glioma tumor invasion in Matrigel and spheroid invasion assay models. RNAi for uPAR and MMP-9 inhibited cell proliferation, and significantly reduced the levels of phosphorylated forms of MAPK, ERK, and AKT signaling pathway molecules when compared with parental and empty vector/scrambled vector-transfected SNB19 cells. Furthermore, using RNAi to simultaneously target two proteases resulted in total regression of pre-established intracerebral tumor growth. Our results provide evidence that the use of hairpin siRNA expression vectors for uPAR and MMP-9 may provide an effective tool for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15824107     DOI: 10.1074/jbc.M408520200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells.

Authors:  Fan Lin; Yuyuan Li; Jie Cao; Shaofeng Fan; Jifeng Wen; Guanghui Zhu; Hong Du; Yanxiao Liang
Journal:  Mol Biol Rep       Date:  2010-12-29       Impact factor: 2.316

2.  Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9-mediated EMT.

Authors:  Swapna Asuthkar; Arun Kumar Nalla; Christopher S Gondi; Dzung H Dinh; Meena Gujrati; Sanjeeva Mohanam; Jasti S Rao
Journal:  Neuro Oncol       Date:  2011-08-02       Impact factor: 12.300

3.  Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells.

Authors:  Barbara S Paugh; Lauren Bryan; Steven W Paugh; Katarzyna M Wilczynska; Silvina M Alvarez; Sandeep K Singh; Dmitri Kapitonov; Hanna Rokita; Sarah Wright; Irene Griswold-Prenner; Sheldon Milstien; Sarah Spiegel; Tomasz Kordula
Journal:  J Biol Chem       Date:  2008-12-11       Impact factor: 5.157

4.  Simultaneous downregulation of uPAR and MMP-9 induces overexpression of the FADD-associated protein RIP and activates caspase 9-mediated apoptosis in gliomas.

Authors:  Christopher S Gondi; Dzung H Dinh; Meena Gujrati; Jasti S Rao
Journal:  Int J Oncol       Date:  2008-10       Impact factor: 5.650

5.  Sphingosine-1-phosphate regulates glioblastoma cell invasiveness through the urokinase plasminogen activator system and CCN1/Cyr61.

Authors:  Nicholas Young; Dennis K Pearl; James R Van Brocklyn
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

6.  Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.

Authors:  Lauren Bryan; Barbara S Paugh; Dmitri Kapitonov; Katarzyna M Wilczynska; Silvina M Alvarez; Sandeep K Singh; Sheldon Milstien; Sarah Spiegel; Tomasz Kordula
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

7.  MMP-9, uPAR and cathepsin B silencing downregulate integrins in human glioma xenograft cells in vitro and in vivo in nude mice.

Authors:  Krishna Kumar Veeravalli; Chandramu Chetty; Shivani Ponnala; Christopher S Gondi; Sajani S Lakka; Daniel Fassett; Jeffrey D Klopfenstein; Dzung H Dinh; Meena Gujrati; Jasti S Rao
Journal:  PLoS One       Date:  2010-07-15       Impact factor: 3.240

8.  Suppression of uPAR retards radiation-induced invasion and migration mediated by integrin β1/FAK signaling in medulloblastoma.

Authors:  Arun Kumar Nalla; Swapna Asuthkar; Praveen Bhoopathi; Meena Gujrati; Dzung H Dinh; Jasti S Rao
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

9.  Progress on antiangiogenic therapy for patients with malignant glioma.

Authors:  Manmeet S Ahluwalia; Candece L Gladson
Journal:  J Oncol       Date:  2010-04-06       Impact factor: 4.375

10.  The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine.

Authors:  P Bhoopathi; C Chetty; M Gujrati; D H Dinh; J S Rao; S S Lakka
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.